Skip to main content

Enzo Lab Approved by Pennsylvania

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem today announced that its clinical lab has been approved by Pennsylvania.

The Enzo Clinical Labs is CLIA approved and CAP accredited but in order to operate in Pennsylvania needs separation approval from regulators in that state.

The company also has pending license application in Maine, Maryland, and California.

The license from Pennsylvania is a "significant step in our ability to solicit business and accept specimens from locations" other than the metropolitan New York City area," Kevin Krenitsky, president of Enzo's Clinical Labs division, said in a statement. The lab is also approved by New York state.

"Patient care ins moving increasingly to predictive diagnostics utilizing markers and gene-based programs, and Enzo Clinical Labs, owing to its highly regarded New York state certification, is increasingly focused on developing into a national leader for the application of esoteric testing and the diagnosis of these specimens," Krenitsky said.

The company is developing its ColonSentry colon cancer risk-stratification assay, multiplex DNA sequencing, alternative amplification/detection methods for pathogens, and other diagnostic tests.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.